Methods of treating cancer using NK cells
AssigneeHoned Life Sciences, LLC
InventorsAvinash Seth, Nikko Lowe, Robert D. Fish
Life of this patent
Estimating the term…
Abstract
Methods for generating clinically safe NK cells derived from non-fully differentiated stem cells and their use in treating cancer are provided. The non-fully differentiated stem cells are co-cultured with endogenous NK cells isolated from adipocyte-containing tissue to generate a high percentage of clinically safe NK cells, where anti-tumor activity of the clinically safe NK cells in vitro is similar to that of endogenous NK cells. Optimized Production of the clinically safe autologous NK cells from stem cells provides platform for treating cancer patients by applying an effective adoptive immunotherapy ranging from the early to terminal stages.
Claims7
A method of generating a CAR expressing NK cells (CARNK cells), comprising;
- isolating endogenous NK cells from a cluster of adipocytes;
- culturing non-fully differentiated stem cells;
- inducing differentiation of non-fully differentiated stem cells into stem cell derived NK cells by co-culturing the cultured non-fully differentiated stem cells with the endogenous NK cells, wherein the non-fully differentiated stem cells and the endogenous NK cells are separated by a barrier when in culture;
- and
- modifying the stem cell derived NK cells and the endogenous NK cells to express chimeric antigen receptor (CAR) to generate CARNK cells.
Dependencies are inferred from the claim text.